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In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS mutations of the primary tumour are
associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively. However, the EGFR and K-RAS
mutation status in metastases is not well studied. We compared the mutation status of these genes between the primary tumours
and the corresponding metastases of 25 patients. Epidermal growth factor receptor and K-RAS mutation status was different between
primary tumours and corresponding metastases in 7 (28%) and 6 (24%) of the 25 patients, respectively. Among the
25 primary tumours, three ‘hotspot’ and two non-classical EGFR mutations were found; none of the corresponding metastases had
the same mutation pattern. Among the five (20%) K-RAS mutations detected in the primary tumours, two were maintained in the
corresponding metastasis. Epidermal growth factor receptor and K-RAS mutations were detected in the metastatic tumours of three
(12%) and five (20%) patients, respectively. The expressions of EGFR and phosphorylated EGFR showed 10 and 50% discordance, in
that order. We conclude that there is substantial discordance in EGFR and K-RAS mutational status between the primary tumours and
corresponding metastases in patients with NSCLC and this might have therapeutic implications when treatment with TKIs is
considered.
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Lung cancer is the most frequent solid tumour and represents the
leading cause of cancer death throughout the developed world.
Almost 70% of patients with non-small-cell lung carcinoma
(NSCLC) present with locally advanced or metastatic disease at
the time of diagnosis. Non-small-cell lung carcinoma is char-
acterised by the accumulation of multiple genetic alterations
(Marsit et al, 2004; Yokota and Kohno, 2004; Garnis et al, 2006).
Mutations within the tyrosine kinase domain of epidermal growth
factor receptor (EGFR) account for increased sensitivity to tyrosine
kinase inhibitors (TKIs; gefitinib and erlotinib) and they are
associated with prolonged overall survival (Lynch et al, 2004; Paez
et al, 2004; Perez-Soler et al, 2004; Chou et al, 2005; Taron et al,
2005; Hirsch, 2006). However, the point mutation T790M and an
insertion mutation in exon 20 were associated with resistance to
TKIs (Gazdar and Minna, 2005). Furthermore, recent studies have
shown that the expression of EGFR as assessed by gene copy
number, mRNA and protein levels could be used to predict
responsiveness to therapy with TKIs (Hirsch et al, 2005; Taron
et al, 2005; Dacic et al, 2006; Dziadziuszko et al, 2006; Endo et al,
2006). In addition, several clinicopathological characteristics, such
as adenocarcinoma histology, non-smoking history, female gender
and Asian origin, are also associated with a higher probability of
response to TKIs, whereas the presence of K-RAS mutations seems
to be correlated with primary resistance to these agents (Tokumo
et al, 2005; Tsao et al, 2005; van Zandwijk et al, 2007). Thus, an
emerging issue concerning EGFR-targeted therapy is to identify
the best method for selecting patients who are more likely to
benefit from EGFR inhibition.
Advanced NSCLC metastasises systemically to diverse sites, such
as the brain, bone, adrenal glands and liver. The classical model for
the metastatic process suggests that most cells of a given primary
tumour have low metastatic potential and only a few cells acquire
enough somatic mutations to become metastatic (Bernards
and Weinberg, 2002). An alternative model proposes that the
metastatic potential is encoded in the mass of a given primary
tumour that has progressed to a pre-metastatic state, after
which metastases may randomly occur without any further gene
expression changes (van ‘t Veer et al, 2002; Hynes, 2003; Van’t
Veer and Weigelt, 2003). Taking into account these two models, a
critical issue for the treatment of metastatic NSCLC is the question
of genetic variability and differences between the primary tumour
and the corresponding metastases. In the majority of studies,
EGFR and K-RAS status was determined on the primary tumours
and there are very few data concerning those of corresponding
metastases (Italiano et al, 2006; Matsumoto et al, 2006). Therefore,
it is unclear whether the same EGFR and K-RAS mutations are also
present in the metastatic lesions or whether clones with different
mutations are responsible for the generation of metastases.
In this study, the mutation status of EGFR and K-RAS as well as
the EGFR and p-EGFR expressions on the primary tumours and
the corresponding metastatic lesions were evaluated in 25 patients
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swith advanced NSCLC. The objective of this study was to
investigate the prevalence of EGFR and K-RAS mutations in
metastases and to examine whether these mutations and the EGFR
expression patterns are discordant between the primary tumours
and the corresponding metastases. Secondary objectives were to
explore whether the EGFR expression pattern correlated to EGFR
and/or K-RAS mutations in both the primary tumours and
corresponding metastases.
PATIENTS AND METHODS
Patients
Patients, aged 418 years old, with histologically confirmed NSCLC
who underwent biopsy or surgical excision of the primary tumour
and the corresponding metastases were included in this retro-
spective analysis. Histological type was determined according to
the World Health Organization criteria, and the stage of the disease
corresponds to that of the time of primary diagnosis. Smoking
history was obtained during the patient’s first evaluation. All
patients gave their informed consent for using their tumour
sample for molecular and pathologic analysis. The study has been
approved by the Ethics and Scientific Committees of our
institution.
DNA extraction and mutation analysis
All tumour samples were formalin-fixed paraffin-embedded
tissues. Sections of a paraffin block corresponding to one
representative area of the tumour were stained with haematox-
ylin/eosin, and the presence of tumour tissue was verified by an
experienced pathologist. Subsequently, tissue samples from at least
three serial sections were microdissected (piezo power Eppendorf
Microdissector; Eppendorf, Germany) to ensure that specimens
contained at least 80% tumour cells; sections of 5mm thickness
were also collected from adjacent normal tissue when available,
extracted with xylene and ethanol to remove paraffin and placed in
1% SDS/proteinase K (10mgml
 1)a t5 6 1C overnight. DNA
was extracted using the MasterPure Complete DNA/RNA Puri-
fication kit (Epicentre Biotechnologies, Madison, WI, USA) according
to the manufacturer’s instructions. Exons 18, 19, 20 and 21 of
the EGFR and exon 1 of K-RAS were sequentially amplified by two
rounds of polymerase chain reaction (PCR) and subjected to direct
sequencing. The PCR primers for EGFR amplification were as follows:
155273L23: 50-TCCCAAACACTCAGTGAAACAAA-30; 155348L22:
50-TGGTCTCACAGGACCACTGATT-30; 154838U22: 50-TCAGAGC
CTGTGTTTCTACCAA-30; 154899U20: 50-TCCAAATGAGCTGGCA
AGTG-30; 55634U24: 50-AAATAATCAGTGTGATTCGTGGAG-30;
156027L20: 50-TGTGGAGATGAGCAGGGTCT-30; 156107L22: 50-G
AGGCCAGTGCTGTCTCTAAGG-30; 155750U20: 50-GTGCATCGCT
GGTAACATCC-30; 173160L22: 50-CAGCTCTGGCTCACACTACC
AG-30; 173076L19: 50-CATCCTCCCCTGCATGTGT-30; 172656U22:
50-GCAGCGGGTTACATCTTCTTTC-30; and 172747U19: 50-GCT
CAGAGCCTGGCATGAA-30. The PCR primers for K-RAS amplifi-
cation were as follows: RASU1: 50-AGGCCTGCTGAAAATGAC
TGAATA-30; RASL1: 50-CTGTATCAAAGAATGGTCCTGCAC-30;
RASU2: 50-AAAATGACTGAATATAAACTTGTGG-30; RASL2: 50-C
TCTATTGTTGGATCATATTCGTC-30. The first PCR was carried
out in a total volume of 10ml contained 1/10 of the extracted
genomic DNA using 1U of Platinum Taq DNA polymerase
(Invitrogen Corporation, Carlsbad, CA, USA). The initial denaturing
step was at 941C for 15min, followed by 35 cycles of denaturing
step at 941C for 20s, annealing step at 601C for 30s and extension
step at 721C for 1min, ending with a final extension step at 721C
for 7min. Nested PCR was carried out in a total volume of 20ml
and the conditions were identical to the first PCR. The PCR
products are directly sequenced by dye terminator sequencing
(ABI BigDye Terminator kit, v3.1, Applied Biosystems, Foster City,
CA, USA), purified by ethanol precipitation and separated by
capillary electrophoresis on an ABI 3100 Avant genetic analyzer
(Applied Biosystems). Sequence analysis was carried out by
Seqscape software (Applied Biosystems) and manually by two
reviewers (AK and AV). All sequence variations were confirmed by
sequencing in both directions and by an independent PCR
amplification when sufficient material was available.
The sensitivity of our methodology was evaluated by determin-
ing the minimum frequency of EGFR and K-RAS mutations
required for detection in our system. This was accomplished by
performing mixing experiments using cell lines with and without
EGFR (H2073-wt-EGFR and HCC827-Del19-EGFR)o rK-RAS
(H2073-wt-K-RAS and A549-G12D-K-RAS) mutations. These
experiments demonstrated that the Del19 and K-RAS mutations
could be detected when present in 10 and 20% of the cells in the
sample, respectively (data not shown).
Immunohistochemistry for EGFR
The paraffin-embedded tissues were cut at 4mm thickness and
were deposited on SuperFrost/Plus Slides (O.Kindler GmbH,
Freiburg, Germany). After deparaffinisation, the slides for EGFR
were treated with proteinase K (Code S3020, DakoCytomation,
Glostrup, Denmark) for 5min at room temperature, and those for
p-EGFR were treated with EDTA at pH 8 in a microwave oven three
times for 5min at 500W for antigen retrieval. The primary anti-
EGFR antibody (mouse monoclonal, clone H11, code M3563, Dako-
Cytomation) was used at a dilution of 1:50 (v/v) and incubated
for 1h at room temperature. The primary anti-phospho-EGFR
antibody (rabbit monoclonal, pY1173-EGFR, code no. 4407, Cell
Signalling, Danvers, MA, USA) was used at a dilution of 1:200 (v/
v) and incubated overnight at 41C. For the detection of antigen-
antibody reaction, the UltraVision detection system AP Polymer
kit (Cat no. TL-125-AL, Lab Vision, Fremont, CA, USA) was used
according to the manufacturer’s instructions. Fast red was used as
chromogen for 20min; the sections were counterstained with
Mayer’s haematoxylin for 3min, subsequently rinsed in ammo-
nium and finally mounted with glycergel. A positive (an NSCLC
tumour specimen with known positivity) and a negative (omission
of primary antibody) control were used. The stained sections were
independently evaluated by two pathologists (AK and ES).
Immunoreactions of EGFR were graded as 3þ when strong
complete membrane staining was observed in more than 10% of
the tumour cells, as 2þ when more than 10% of the tumour cells
showed weak-to-moderate complete membrane staining, as 1þ
when partially, faint membrane stain was detected in more than
10% of the tumour cells and as 0 when no staining at all or
membrane staining in less than 10% of the tumour cells was
observed. In this study, we arbitrarily classified EGFR expression
status in two subsets; the 2þ or 3þ signals were considered as
EGFR overexpression and the 0 or 1þ signals as non-expression
(Koutsopoulos et al, 2007).
A paraffin block from the HCC827 lung epithelial adenocarci-
noma cell line and commercially available positive controls
(SignalSlide Phospho-EGF Receptor (Tyr1173) IHC Controls, code
no. 8102, Cell Signalling) was used to validate the antibody for
p-EGFR. pY1173-EGFR immunostaining was mainly membranous
and was graded as 0 (o5% positive cells), 1þ (5–19% positive
cells), 2þ (20–50% positive cells) and 3þ (450% positive cells)
(Cortas et al, 2007).
Statistical analysis
McNemar test was used to compare the EGFR and K-RAS status
between primary tumours and related metastatic sites. Differences
were considered statistically significant when the P-value was
o0.05. All statistical tests were two-sided.
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Patient characteristics
Twenty-two (88%) patients were men and 22 (88%) were active or
former smokers and their median age was 55 years (range, 41–70).
Eighteen (72%) patients had adenocarcinomas (ADC) and 21
(84%) patients had stage III or IV disease. Among the 50 samples
analysed (25 primary tumours and 25 metastases), 26 (52%)
samples were surgical and 24 (48%) biopsies. The primary tumour
tissue was the lung (n¼25 patients); and the origin of the
metastatic sample was lung (n¼9 patients), thoracic wall (n¼5
patients), adrenal gland (n¼4 patients), brain (n¼3 patients),
bone (n¼2 patients), liver (n¼1 patient) and skin (n¼1 patient).
Metastases were metachronous in all cases; the median time
elapsed between resection of the primary tumour and the
corresponding metastatic site was 30 months (range, 4–143).
The patients’ clinicopathologic characteristics are presented in
Table 1. Nine (36%) patients were treated with gefitinib in the
context of an Expanded Access Program (Table 2).
EGFR mutation status of the primary tumours and the
corresponding metastasis
The EGFR mutation status of the primary tumours and the
corresponding metastases is presented in Table 2. Epidermal
growth factor receptor mutations were detected in the primary
tumours of five (20%) patients; of these, three of them were the
well-characterised ‘hotspot’ mutations in exon 19 (Del746-750 and
E746V; case nos. 20, 23 and 18) and the remaining two were novel
point mutations in exons 18 and 21 (L692P and G857E; case nos. 17
and 19), respectively. The corresponding metastases of the Del746-
750 (case no. 23), E746V (no. 18), L692P (no. 17) and G857E (no.
19) mutant primary tumours were wild type with respect to EGFR
mutation status. Epidermal growth factor receptor mutations were
detected in the metastatic tumours of three (12%) patients
(Table 2). The metastasis of one of these patients showed the
same EGFR mutation (Del19) as the primary tumour as well as an
additional one, the T790M in exon 20 (no. 20); conversely, the
other two patients carried two novel mutations in exon 18 (L692P
and V717A; no. 12) and the T847A (no. 13) in exon 21, which could
not be detected in the patients’ primary tumour samples. We have
confirmed that the non-classical mutations detected in our series
are not single nucleotide polymorphisms by mutation analysis of
matched normal tissue or blood (data not shown).
Consequently, the EGFR gene status could be classified as:
(i) EGFR wild type in both primary tumour and metastasis (n¼18
patients; 72%), and (ii) EGFR mutations detected only in the
primary tumour (n¼4 patients; 16%) or the metastases (n¼2
patients; 8%) or both (n¼1 patient; 4%). Therefore, EGFR
mutation status showed a discordance of 28% (7 of 25 patients)
(McNemar test, P¼0.688) between the primary tumour and
corresponding metastasis (Table 3).
EGFR and p-EGFR expression by IHC in the primary
tumour and the corresponding metastases
E ´n 19 patients sufficient tumour tissue was available for immuno-
histochemical analysis of EGFR (Tables 2 and 4). The incidence of
EGFR overexpression (grade 2þ,3þ) was 26.5% in both primary
and metastatic tumours. Concordance between the primary
tumour and the corresponding metastases was observed in 17
(89.5) patients (Cohen’s Kappa¼0.729, P¼0.001) and among
them EGFR was overexpressed in four (21.1%). Discordance was
observed in two (10.5%) patients (nos. 14 and 15) (McNemar test,
P¼1). Evaluable paired tissue specimens for p-EGFR analysis by
IHC were available in 16 patients. Three out of 16 (18.8%) primary
Table 1 Patient’s clinicopathological characteristics
Case Age Sex Histology Stage
a
Smoking
status
Tissue sample
b
P
c/M
d
Metastatic
site
Time
e
elapsed between
P and M
Treatment administered
between P and M
1 60 M ADC IV Active B/B Skin 10 Taxane–platinum
2 54 M SCC II Active S/S Lung 20 None
3 70 M ADC III Former B/B Lung 55 Taxane–gemcitabine
4 44 M ADC III Active S/B Lung 65 Taxane–platinum–
gemcitabine
5 55 M ADC III Active S/S Lung 23 Taxane–platinum
6 63 M ADC IV Active B/B Lung 4 None
7 66 M ADC/BAC III Never S/B Thoracic wall 12 None
8 57 M LCC III Active S/B Thoracic wall 4 Taxane–platinum
9 55 M ADC III Former S/S Thoracic wall 15 Taxane–platinum
10 49 M ADC II Active S/S Adrenal gland 28 Taxane–platinum
11 50 F ADC IV Active B/B Brain 36 Taxane–platinum
12 68 M ADC III Active S/S Brain 10 Taxane–platinum
13 44 M GCC IV Active B/B Lung 74 Taxane–platinum
14 56 M ADC IV Active B/S Adrenal gland 17 None
15 53 M ADC III Active S/B Thoracic wall 2 Taxane–platinum
16 41 M ADC IV Active S/B Lung 143 None
17 56 M ADC IV Former B/S Adrenal gland 36 Taxane–platinum–
gemcitabine, gefitinib
18 42 F ADC II Never S/S Liver 30 Taxane–platinum, gefitinib
19 55 M ADC III Former S/B Bone 2 None
20 46 M SCC III Active S/B Lung 45 Taxane–platinum–gefitinib
21 62 M LCC III Never S/B Bone 48 Platinum–gemcitabine
22 67 M ADC IV Active B/S Adrenal gland 14 None
23 53 M ADC IV Active S/B Brain 21 None
24 52 F ADC/BAC II Active S/S Lung 51 None
25 63 M ADC IV Active B/B Thoracic wall 1 None
ADC¼adenocarcinoma; ADC/BAC¼adenocarcinoma with bronchoalveolar features; GCC¼giant cell carcinoma; LCC¼large cell carcinoma; F¼female; M¼male;
SCC¼squamous carcinoma.
aStage, corresponds to that of the time of primary diagnosis.
bTissue sample: B, biopsy; S, surgery.
cP, primary tumour.
dM, metastasis.
eTime, months.
Comparison of EGFR and K-RAS gene status in NSCLC
A Kalikaki et al
925
British Journal of Cancer (2008) 99(6), 923–929 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sand seven out of 16 (43.8%) metastatic tumours expressed
phosphorylated EGFR (pY1173-EGFR-positive). Discordance bet-
ween the primary and metastatic tumours was observed in eight
(50%) patients (McNemar test, P¼1) (Tables 2 and 4). There was
no correlation between the expression of EGFR and pY1173-EGFR.
In order to confirm our findings, we repeated the immuno-
histochemistry from serial sections in all tumour specimens that
exhibited EGFR-negative and p-EGFR-positive staining and the
obtained results were identical. Epidermal growth factor receptor
gene copy number was also investigated by fluorescence in situ
hybridisation in eight patients (nos. 2, 5, 7, 9, 10, 13, 19 and 24) for
whom paired tissue specimens were available; amplification of
EGFR gene was not detected in any of these tumour specimens.
K-RAS mutation status of the primary tumours and the
corresponding metastases
Primary and metastatic tumours were also assessed for K-RAS
mutations (Table 2). K-RAS mutations were detected in the
primary tumours of five (20%) patients (nos. 8, 10, 22, 23 and 25)
and in the metastatic tumours of five (20%) patients (nos. 9, 10, 11,
16 and 23), respectively. Two patients (nos. 10 and 23) carried the
same K-RAS mutations in both primary and metastatic tumours
(Table 2). One of them (case no. 23) carried the Del746-750 EGFR
mutation in the primary tumour but not in metastasis. This was
confirmed by three independent PCRs from three genomic DNAs
extracted from serial sections of the paraffin blocks. Discordance
in K-RAS mutation status between the primary tumours and the
corresponding metastases was observed in six (24%) patients
(McNemar test, P¼1) (Table 3).
Response to gefitinib according to EGFR and K-RAS
mutation status
Nine patients received gefitinib as first (nos. 23 and 18), third (nos.
15, 16, 19 20 and 22) or fourth (nos. 14 and 17) line treatment.
Three patients received gefitinib before the biopsy of metachro-
nous metastases (nos. 17, 18 and 20) and six received gefitinib after
the biopsy of metastases (nos. 14, 15, 16, 19, 22 and 23). Five
patients (56%) achieved stable disease and four (44%) progressive
disease (Table 2). All patients who experienced progressive disease
on gefitinib were wild type regarding the EGFR mutation status in
both primary tumours and metastases (nos. 14, 15, 16, and 22), of
these, two patients carried K-RAS mutations in the primary
Table 2 EGFR and K-RAS status in paired primary and metastatic tumours
EGFR mutation status EGFR expression p-EGFR expression K-RAS mutation status
Case Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis Gefitinib Response
1 wt wt 1+ 1+ 0 2+ wt wt No —
2 w t w t 3 +3 +1 +1 + w t w tN o —
3 wt wt 0 1+ 0 0 wt wt No —
4 wt wt 3+ 2+ 0 1+ wt wt No —
5w t w t 0 0 0 0 w t w t N o—
6 wt wt 1+ 0 0 0 wt wt No —
7 wt wt 0 1+ 0 0 wt wt No —
8 wt wt 1+ 0 0 0 G12S wt No —
9 wt wt 1+ 1+ 0 1+ wt G13S No —
10 wt wt 2+ 3+ 0 0 G12V G12V No —
11 wt wt ND 2+ ND 2+ wt G12S No —
12 wt L692P
V717A
1+ 0 ND 2+ wt wt No —
13 wt T847A 0 0 0 1+ wt wt No —
14 wt wt 3+ 0 1+ 0 wt wt Yes PD
15 wt wt 0 2+ ND 2+ wt wt Yes PD
16 wt wt 0 0 0 2+ wt G12A Yes PD
17 L692P wt 0 1+ 0 0 wt wt Yes SD
18 E746V wt 0 0 ND 0 wt wt Yes SD
19 G857E wt 0 0 0 1+ wt wt Yes SD
20 E746-A750
del
E746-A750
del T790M
2+ 3+ 2+ 0 wt wt Yes SD
21 wt wt ND ND ND ND wt wt No —
22 wt wt ND ND ND ND G12D wt Yes PD
23 E746-A750
del
wt ND ND ND ND G12C G12C Yes SD
24 wt wt ND ND ND ND wt wt No —
25 wt wt ND ND ND ND G12C wt No —
Table 3 Combined analysis of EGFR and K-RAS mutation status
Primary/metastatic tumour
wt/wt wt/mut mut/wt mut/mut Discordance
EGFR 18 (72%) 2 (8%) 4 (16%) 1 (4%)
a 7 cases (28%)
K-RAS 17 (68%) 3 (12%) 3 (12%) 2 (8%) 6 cases (24%)
aDel19/Del19 and T790M.
Table 4 EGFR expression as assessed by IHC
Primary tumour status/metastasis status
+ve/+ve  ve/ ve +ve/ ve  ve/+ve Discordance
EGFR 4 (21.1%) 13 (68.4%) 1 (5.3%) 1 (5.3%) 2/19 (10.6%)
p-EGFR (Y1173) 1 (6.2%) 7 (43.8%) 2 (12.5%) 6 (37.5%) 8/16 (50%)
IHC¼immunohistochemistry.
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stumour (no. 22) or metastasis (no. 16). All the five patients with
stable disease on gefitinib carried EGFR mutations in their primary
tumours (nos. 17, 18, 19, 20 and 23). Of these, three patients
carried the well-characterised activating mutations in exon 19
(nos. 18, 20 and 23) and two carried EGFR mutations of unknown
function (nos. 17 and 19). Patient nos. 18 and 20 who received
gefitinib before metachronous metastasis developed metastatic
tumours, which were either wild type in respect to EGFR mutation
status (no. 18) or had acquired resistance because of the T790M
EGFR mutation (no. 20). Patient no. 23, who received gefitinib
after metastasis, carried both EGFR and K-RAS mutations in the
primary tumour and the same K-RAS mutation in metastasis.
DISCUSSION
Several studies have shown that activating EGFR mutations
in exons 18, 19 and 21 have been associated with a 75–95%
objective response rate with EGFR TKIs, whereas the K-RAS
mutations were associated with a lack of sensitivity to these
agents (Pao et al, 2005; Sharma et al, 2007). Epidermal growth
factor receptor gene amplification and protein expression
have also been considered as predictors of clinical benefit with
gefitinib (Hirsch et al, 2006). However, in clinical studies, a
significant percentage of patients presented clinical benefit when
treated with TKIs irrespective of the expression and mutational
status of EGFR (Sharma et al, 2007). As, in most studies, EGFR
expression and mutations were determined on the primary
tumour, the observed clinical benefit of patients with wild-type
EGFR or the absence of response to TKIs of patients with EGFR
mutations could be due to discordance in the EGFR mutation
status or expression between the primary tumour and the
corresponding metastasis.
This study demonstrated the existence of a significant dis-
cordance of EGFR and K-RAS mutations occurring in primary
tumours and their corresponding metastases in patients with
NSCLC. The discordance in EGFR mutation status was 28% and
that in K-RAS was 24%. Similarly, two other studies in paired
NSCLC tumours showed a discordance of 32 and 27% regarding
the EGFR gene copy number (Italiano et al, 2006; Bozzetti et al,
2008), whereas another study including six NSCLC patients of
Asian ethnicity reported a 100% concordance in regard to EGFR
mutation status (Matsumoto et al, 2006). This discrepancy could
be related to the different sites of the metastatic tumours analysed
in this study (five different distant metastases), whereas in the
Matsumoto’s et al study, only tumour samples from brain
metastases were included. Diverse sites of metastases in NSCLC
probably represent different clonal outgrowths. Alternatively, we
cannot exclude that the different ethnicity of patients and/or the
different types of EGFR mutations could be the reason for this
discrepancy (Tsao et al, 2006; Pallis et al, 2007). In this study
including only Caucasian patients, three classical activating (Del19
and E746V) and four non-classical mutations (T847A, L692P-
V717A, L692P and G857E) were detected, whereas in Matsumoto’s
et al study, only classical activating Del19 and L858R mutations
were reported. Concerning the non-classical mutations, it is
unlikely to represent PCR artifacts, as L692F, T847I and G857E
EGFR mutations have been previously reported (Fujimoto et al,
2005; Tsao et al, 2005; Hsieh et al, 2006). Furthermore, the
expression of phosphorylated EGFR (pY1173-EGFR-positive) on
tumour cells from metastatic lesions carrying the T847A and
L692P-V717A mutations strongly suggests that the former might
be activating EGFR mutation. The time elapsed between diagnoses
of the primary tumour and corresponding metastasis in patients
(nos. 13 and 12) carrying the abovementioned mutations was 74.5
and 10 months, respectively. Therefore, acquisition of new
mutations may be developed during the evolution of the metastatic
process.
The administration of TKIs could be an additional explanation
of the observed discordance of EGFR mutations. Three out of
25 patients received gefitinib before the development of a meta-
chronous metastasis, whereas none of the patients reported in the
Matsumoto’s et al study had exposed to TKIs. It is known that
NSCLC patients with EGFR-dependent primary tumours when
treated with TKIs can develop metastases, in which either the
EGFR signalling is negated or resistance is acquired due to
secondary EGFR mutations like T790M or MET amplification
(Daneshmand et al, 2003; Gazdar and Minna, 2005; Engelman et al,
2007; Lutterbach et al, 2007). It is interesting to note that in
patients who had not been exposed to TKIs before biopsy of
metastatic lesions, a 18% (4 out of 22 patients) discordance was
observed between primary tumours and related metastases.
However, a final explanation of the observed discordance, which
cannot be excluded, concerns the low-frequency intratumoral
heterogeneity for the occurrence of EGFR mutations (Sakurada
et al, 2008).
Our findings concerning the K-RAS mutation status are in
agreement with a previous study demonstrating that the K-RAS
mutational status of the primary tumour does not always predict
the status of bone metastasis in NSCLC (Badalian et al, 2007). A
similar phenomenon was also reported in patients with colorectal
cancer (Tortola et al, 2001). Although K-RAS mutations seem to be
associated with the early development of NSCLC, it cannot be
excluded that K-RAS mutations are lost later during tumour
progression (Burmer and Loeb, 1989; Li et al, 1994). This may, in
part, explain the discordance in the K-RAS mutation status
between primary tumours and metachronous metastases.
Another possibility for the observed discordance in the EGFR
and K-RAS mutation status could be related to the administered
chemotherapy. However, as shown in Table 1, among the 10
patients who had not received any treatment before the mutation
analysis of the metastatic lesions, 5 developed metastases with
different mutation status from that of the corresponding primary
tumours. Thus, although tumour clone selection through the
various treatments could be an explanation for the different
molecular pattern in the primary tumour and metastatic site, our
findings suggest that the metastasis genotype could be different
from that of the corresponding primary tumour irrespectively of
administered chemotherapy.
Previous studies have shown that EGFR and K-RAS mutations
are mutually exclusive, suggesting the presence of different
pathways of lung carcinogenesis. However, as previously reported,
our data show that K-RAS mutation may coexist with EGFR
mutation (Fujimoto et al, 2005; Han et al, 2006). Among the five
patients with EGFR mutations in primary tumours, one patient
concomitantly had K-RAS mutation (G12C with deletion in exon
19). In the metachronous metastasis, only the K-RAS mutation was
retained. This patient received gefitinib after the biopsy of
metastatic lesion and had stable disease lasting for 3.5 months.
The limited duration of response is compatible with the knowledge
that the presence of K-RAS mutations is associated with resistance
to TKIs.
In this study, the expression of pY1173-EGFR was different
between primary tumours and corresponding metastases in eight
(50%) patients, whereas EGFR expression was discordant in two
(10%) patients. The apparent lack of correlation between EGFR
and p-EGFR expression has been previously reported and could be
due to the different scoring systems and different sensitivities of
antibodies used to evaluate the EGFR and p-EGFR expressions
(Han et al, 2005). It is well known that overexpression of EGFR is
associated with Tyr phosphorylation of the receptor proteins
and that mutations in the kinase domain may cause consti-
tutive phosphorylation of EGFR (Chen et al, 2006). However,
biochemical studies have shown that variable phosphorylation
rates were associated with different tyrosine phosphorylation sites
in the receptor; G719S mutant receptor had less EGF-induced
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type EGFR, whereas L858R mutant receptor preferentially phos-
phorylated at the Y1068 but not at Y1173 (Sordella et al, 2004;
Chen et al, 2006; Liu et al, 2007).
Clinical investigations suggested a correlation between a high
EGFR gene copy number and EGFR mutations (Cappuzzo et al,
2005; Takano et al, 2005). Our study failed to demonstrate such a
correlation probably due to limited number of cases analysed.
Evaluable paired tissue specimens for fluorescence in situ
hybridisation analysis were available for eight patients. Among
them, two (nos 13 and 19) patients presented different EGFR
mutation status in the primary tumours and corresponding
metastases; however, these two patients harbour non-classical
EGFR mutations (T847A and G857E) and did not show different
EGFR amplification patterns between paired samples. On the basis
of these findings, at the present time, we consider that only the
genetic differences unequivocally distinguish EGFR-dependent
tumours, which are likely to be sensitive to TKIs from the tumours
that could be resistant to these agents (Papadopoulos et al, 2006).
In conclusion, our findings indicate a substantial discordance of
EGFR and K-RAS mutations between the primary tumours and the
corresponding metastases in NSCLC and underline the need to
consider the genotype of both primary and metastatic tumours for
selecting patients who will respond to therapy with TKIs.
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